AstraZeneca Plc (AZN) reported a 22% dip in earnings for the fourth quarter to 82 cents per share, weighed down higher costs. Core earnings for the quarter stood at $1.58 per share. Analysts were expecting the UK-based pharmaceutical giant to post earnings of 73 cents per share.
Total revenues rose 11% to $6.4 billion as product sales improved 5% on the strong performance of new medicines and the sustained strength in emerging markets. Analysts were expecting total revenue of $6.16 billion.
Oncology sales surged by 58% to $1.77 billion.
AZN shares popped over 6% during pre-market trading on Thursday. The stock has gained 6.2% in the trailing 52 weeks.
CEO Pascal Soriot said, “Our new medicines performed particularly well across the therapy areas and the Emerging Markets business went from strength to strength. 2019 will be a year of focus on continued pipeline delivery and flawless commercial execution.”
The company provided earnings guidance for fiscal year 2019. During this period, AstraZeneca expects Core EPS in the range of $3.50 to $3.70, as product sales are anticipated to increase in the high single-digits.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference, and much more!
Most Popular
Micron (MU) projects record Q3 revenue, powered by strong HBM sales
Micron’s (NASDAQ: MU) second-quarter report underscores its leadership position in high-bandwidth memory (HBM) chips and AI-driven data center solutions. The expanding portfolio of high-margin products gives the memory chipmaker a
FedEx (FDX): Uncertain demand environment and inflationary pressures dampen outlook
Shares of FedEx Corp. (NYSE: FDX) were down 6% on Friday after the company reported its earnings results for the third quarter of 2025 and lowered its outlook for the
NKE Earnings: Nike reports lower sales for Q3 2025
NIKE, Inc. (NYSE: NKE) has reported a decline in earnings for the third quarter of 2025, hurt by a slowdown in sales across all major markets and operating segments. The
